NICOX overview

Press Release Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont Blanc NCX 470 partnering efforts will focus on routes for bringing the product to market in the U.S. Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 December 2, 2024 – release at 7:30 am CET Sophia...

Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025 Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024 The Company estimates that it is financed into Q3 2025 October 17, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA...

Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox’s net share of the VYZULTA royalty to Soleus Soleus investing $1.5 million (€1.37 million) in Nicox shares, issued at €0.3144 per share, representing a 20% premium to the closing price on October 11, 2024, with attached warrants valued at $0.75 million (€0.69 million) at an exercise price of €0.5240 per share, representing a 100% premium...

Press Release Nicox Announces Approval of ZERVIATE in China Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE ® for ocular itching in China ZERVIATE ® launch in China will add a further royalty revenue stream for Nicox September 18, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Chinese partner, Ocumension Therapeutics, has...

Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and Trophos Michele Garufi, former Chairman and CEO of Nicox, hands over his Board position after over more than 25 years at the company he co-founded The Nicox Board has now been entirely renewed to bring in the expertise to support the Company’s strategic direction going forward September 4 th , 2024 – release at...

Press Release Nicox announces attendance at upcoming conferences July 19 th , 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its attendance at several upcoming international conferences: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 (Virtual) H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024 (New York) Investor...

Press Release Nicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue 1 €1.0 million) for second quarter 2024 Nicox Group cash of €7.8 million on 30 June 2024 which finances the Company until at least February 2025 July 18 th , 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position for Nicox SA and its subsidiaries...

Press Release Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Damian Marron is an experienced healthcare executive, non-executive Director/Chair and advisor Marc Le Bozec is an experienced life sciences entrepreneur with a background in finance, organization and strategic consulting Jean-François Labbe retires as Chair and member of the Board at the completion of his term; Les Kaplan has also decided to step down from the Board July 16...